A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study
Clin. transl. oncol. (Print)
; 13(9): 686-691, sept. 2011. tab
Article
in En
| IBECS
| ID: ibc-125874
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
INTRODUCTION: The objective was to evaluate a dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide (AC) as neoadjuvant treatment for patients with locally advanced breast cancer. PATIENTS AND METHODS: Ninety-nine patients were included and received 100 mg/m(2) of docetaxel every two weeks for four cycles followed by 60 mg/m(2) of doxorubicin and 600 mg/m(2) of cyclophosphamide every two weeks for four cycles. Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) was administered systematically to all patients. RESULTS: Efficacy and toxicity analyses were carried out on an intention-to-treat basis. After treatment, complete pathological response in the breast and lymph nodes was confirmed in 15 patients (15%, 95% confidence interval [CI]: 8.4-22.9). Clinical response rate was 74% (95% CI: 65-82), of which 19% were complete responses. Breast-conserving surgery could be performed in 41% of patients. The dose-dense schedule was generally well tolerated. The most important grade 3/4 toxicities per patient were cutaneous toxicity (12.1%) and hepatic dysfunction (9.1%) during docetaxel administration, and neutropenia (28.1%) and leucopenia (8.3%) with AC. CONCLUSION: A dose-dense schedule of docetaxel followed by AC as neoadjuvant treatment is an effective and safe treatment for locally advanced breast cancer. Primary prophylaxis with G-CSF, and possibly the change in the sequence of drug administration, appears to play a major role in avoiding the excessive toxicity of dose-dense schedule (AU)
Search on Google
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Breast Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Doxorubicin
/
Carcinoma, Ductal, Breast
/
Cyclophosphamide
/
Taxoids
Type of study:
Evaluation_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2011
Document type:
Article